Study medicine LBS-007 for relapsed leukemia patients
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests how safe and tolerable LBS-007 is for adults with AML or ALL that has come back or is resistant to treatment. It may help people who can’t use standard therapies or have no proven treatment options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult (18 years or older).
- You have confirmed AML or ALL that has relapsed or not responded to treatment.
- You either can’t get standard treatment expected to control the leukemia long-term, or you don’t have other proven options.
- Your daily function is good enough: ECOG score 0 to 2 (can do most normal activities, with limited limitations).
- You are not receiving chemotherapy, radiation, or immunotherapy at the same time.
- You are able to understand the study and follow its rules (can give informed consent).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This is a Phase 1 trial testing a new drug called BSB-2002 in patients with acute myeloid leukemia (AML) that has come back or stopped responding to previous treatments. The drug is designed specifically for patients whose cancer cells have a particular genetic change (NPM1 mutation) and may help control the cancer by activating the immune system.
This trial tests an oral investigational drug (GLB-001) for people with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) that has returned or hasn't responded to other treatments. The goal is to see if it's safe and effective for those who have run out of standard options.
This trial tests a new treatment, BG1805, for people with acute myeloid leukemia (AML) that has come back or not responded to standard therapy. It targets a specific marker on leukemia cells called CLL-1.
This Phase 1 study tests BXCL701 in adults whose acute myeloid leukemia (AML) or high-blast myelodysplastic syndrome (MDS-EB-2) has come back or not responded to prior treatment. The goal is to find a safe dose and see how the treatment affects cancer cells.
This trial tests a new drug called CG009301 for people with blood cancers that have come back or haven't responded to standard treatments. The goal is to see if the drug is safe and works against these cancers.
This study uses advanced tests (genetics and other 'omics' methods) to better understand your leukemia and find a treatment that targets its specific features. It may help if standard treatments haven't worked or stopped working.
Hear when a new Relapsed or Resistant Acute Leukaemias trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.